skip to Main Content

Spotlight on Liposomal Irinotecan for Metastatic Pancreatic Cancer: Patient Selection and Perspectives

Spotlight on Liposomal Irinotecan for Metastatic Pancreatic Cancer: Patient Selection and Perspectives
Pancreatic ductal adenocarcinoma (PDAC) is the most common histologic type that tends to metastasize early in tumor progression. For metastatic PDAC, gemcitabine had been the mainstay treatment for the past three decades. The treatment landscape has changed since 2010, and current first-line chemotherapy includes triplet drugs like FOLFIRINOX…

Read more . . .


Back To Top